Dinutuximab-beta is a monoclonal anti – GD2 antibody indicated for the treatment of newly diagnosed, relapsed and refractory high-risk neuroblastoma.
It is a form of immunotherapy which binds to GD2, which is over-expressed in neuroblastoma cells and induces antibody and complement-mediated cytotoxicity to eradicate tumor cells.
